1. Search Result
Search Result
Results for "

entry

" in MedChemExpress (MCE) Product Catalog:

111

Inhibitors & Agonists

1

Screening Libraries

4

Fluorescent Dye

3

Biochemical Assay Reagents

17

Peptides

7

Inhibitory Antibodies

12

Natural
Products

16

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138102

    SARS-CoV Infection
    SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM .
    SSAA09E3
  • HY-133735A

    RABV Infection
    GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein .
    GRP-60367 hydrochloride
  • HY-N7934

    (-)-Trachelogenin

    HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-133735

    RABV Infection
    GRP-60367 is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains .
    GRP-60367
  • HY-129116

    SARS-CoV Cathepsin Infection
    SSAA09E1 is a cathepsin L blocker (IC50: 5.33 μM).SSAA09E1 inhibits stages of viral entry. SSAA09E1 can be used for SARS-CoV infection research
    SSAA09E1
  • HY-W278021

    Others Others
    BTA-1 is an uncharged derivative of thioflavin-T. BTA-1 has high affinity for Aβ fibrils and shows very good brain entry and clearance .
    BTA-1
  • HY-156441

    SARS-CoV Infection
    SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
    SARS-CoV-2-IN-65
  • HY-163362

    Reverse Transcriptase PKC HIV Infection
    HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase .
    HIV-1 inhibitor-65
  • HY-144110

    HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    HCV-IN-37
  • HY-131059

    Influenza Virus Infection
    CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process .
    CBS1117
  • HY-157249

    Influenza Virus Infection
    Antiviral agent 43 (compound 16) is a potent and orally active influenza A viruses entry inhibitor. Antiviral agent 43 inhibits replications of influenza A strains VH04-H5N1 and PR8-H1N1 with EC50s of 240 nM and 72 nM, respectively .
    Antiviral agent 43
  • HY-N4100
    Trilobatin
    1 Publications Verification

    HIV SGLT Infection
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd , Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin
  • HY-131069A

    Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .
    MBX2329
  • HY-19663

    NB-818; NPK-1886

    Calcium Channel Cardiovascular Disease
    Lemildipine is a new dihydropyridine calcium entry blocker.
    Lemildipine
  • HY-112913

    CRAC Channel Neurological Disease Metabolic Disease
    SOCE inhibitor 1 is a store-operated calcium entry (SOCE) inhibitor with an IC50 of 4.4 μM.
    SOCE inhibitor 1
  • HY-115488A

    HIV Infection
    BNM-III-170 is able to inhibit HIV-1 viral entry into target cells.
    BNM-III-170
  • HY-144106

    HCV Infection
    HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor .
    HCV-IN-33
  • HY-P1034
    DAPTA
    1 Publications Verification

    D-Ala-peptide T-amide; Adaptavir

    CCR HIV Infection Endocrinology
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
    DAPTA
  • HY-N3222

    HIV Infection Cancer
    Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41. Myriceric acid B is an antitumor agent .
    Myriceric acid B
  • HY-111325
    Synta66
    3 Publications Verification

    CRAC Channel Neurological Disease
    Synta66 is an inhibitor of store-operated calcium entry channel Orai, which forms the pore of the CRAC channel, and used for the research of neurological disease.
    Synta66
  • HY-100039

    HIV Infection
    YYA-021 is a small-molecule CD4 mimic that inhibits HIV entry, with high anti-HIV activity and low cytotoxicity .
    YYA-021
  • HY-N1370
    Tanshinone IIA sulfonate sodium
    5 Publications Verification

    Sodium Tanshinone IIA sulfonate; Tanshinone IIA sodium sulfonate

    CRAC Channel Cardiovascular Disease Cancer
    Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca 2+ entry (SOCE), and is used to treat cardiovascular disorders.
    Tanshinone IIA sulfonate sodium
  • HY-146157

    SARS-CoV Infection
    SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM .
    SARS-CoV-2-IN-22
  • HY-N0248

    HCV Infection Cancer
    Saikosaponin B2 is an active component from Bupleurum chinensis root, acts as an entry inhibitor against HCV infection . Anti-cancer activity .
    Saikosaponin B2
  • HY-100229
    Aloxistatin
    Maximum Cited Publications
    50 Publications Verification

    E64d; E64c ethyl ester

    Cathepsin SARS-CoV Neurological Disease
    Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.
    Aloxistatin
  • HY-150756

    Filovirus Infection
    EBOV-GP-IN-1 (Compound 28) is a potent Ebola entry inhibitor with an IC50 of 0.05 μM against Ebola virus envelope glycoprotein (EBOV-GP) .
    EBOV-GP-IN-1
  • HY-158097

    Influenza Virus Infection
    IAV-IN-2 (Compound MC-22) inhibits for Influenza A Virus (IAV) through blocking the entry of IAV into host cell via clathrin-mediated endocytosis (CME) .
    IAV-IN-2
  • HY-N0360
    Dihydrotanshinone I
    3 Publications Verification

    SARS-CoV Cardiovascular Disease
    Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.
    Dihydrotanshinone I
  • HY-150269

    Others Cancer
    RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer .
    RS5517
  • HY-119293
    K777
    1 Publications Verification

    Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus Infection Cancer
    K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
    K777
  • HY-N2037B

    (S)-Norcoclaurine

    Endogenous Metabolite Others
    (S)-Higenamine ((S)-Norcoclaurine), a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS) .
    (S)-Higenamine
  • HY-P99028

    TMB-355; TNX-355

    HIV Infection
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .
    Ibalizumab
  • HY-P99337

    Ansuvimab-zyk; mAb114

    Filovirus Infection
    Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
    Ansuvimab
  • HY-P9803

    SARS-80R; SARS Antibody-80R

    SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
    Anti-SARS-80R mAb
  • HY-100831
    YM-58483
    10+ Cited Publications

    BTP2

    CRAC Channel Inflammation/Immunology
    YM-58483 (BTP2) is the first selective and potent inhibitor of CRAC channels and subsequent Ca 2+ signals . YM-584832 is a blocker of store-operated Ca 2+ entry (SOCE) .
    YM-58483
  • HY-104074
    Pocapavir
    3 Publications Verification

    SCH-48973; V-073

    Enterovirus Infection
    Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
    Pocapavir
  • HY-153837

    HCV Infection
    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
    ISIS 14803
  • HY-153837A

    HCV Infection
    ISIS 14803 sodium is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
    ISIS 14803 sodium
  • HY-156655A

    STI-1558 sodium

    SARS-CoV Cathepsin Infection
    Olgotrelvir sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
    Olgotrelvir sodium
  • HY-N2037C

    (S)-Norcoclaurine hydrobromide

    Endogenous Metabolite Others
    (S)-Higenamine ((S)-Norcoclaurine) hydrobromide, a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine hydrobromide is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS) .
    (S)-Higenamine hydrobromide
  • HY-B1624

    Debrisoquine; Isocaramidine; Ro 5-3307/1

    SARS-CoV Ser/Thr Protease Infection
    Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin can be used for antiviral research .
    Debrisoquin
  • HY-100227
    E 64c
    2 Publications Verification

    E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
    E 64c
  • HY-B1558

    MCI-2016 free base

    Calcium Channel Neurological Disease
    Bifemelane is a nootropic compound. Bifemelan causes the first peak by stimulating release from intracellular Ca 2+ stores and the second by capacitive entry through store–operated Ca 2+ channels. Bifemelane will be provided as a pharmacological tool for basic studies on astrocytes .
    Bifemelane
  • HY-126425

    Others Infection
    NCGC00262650 is a potent apical membrane antigen 1-rhoptry neck protein 2 (AMA1-RON2) interaction inhibitor. NCGC00262650 can block entry of merozoites into red blood cells .
    NCGC00262650
  • HY-P990052

    MAD-0004J08

    SARS-CoV Infection
    Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
    Simaravibart
  • HY-P99346

    CT-P59

    SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
    Regdanvimab
  • HY-B1624A

    Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate

    Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin hemisulfate can be used for antiviral research .
    Debrisoquin hemisulfate
  • HY-144107

    HCV Infection
    HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC50 of 0.010 μM and a CC50 (half-maximal cytotoxic concentration) of 8.23 μM .
    HCV-IN-34
  • HY-148072

    SARS-CoV Infection
    MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells .
    MM3122
  • HY-P4810

    T140

    CXCR Infection
    Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
    Polyphemusin II-Derived Peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: